Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

被引:79
作者
Dao, Fanny [1 ]
Schlappe, Brooke A. [1 ]
Tseng, Jill [1 ]
Lester, Jenny [2 ]
Nick, Alpa M. [3 ]
Lutgendorf, Susan K. [4 ,5 ]
McMeekin, Scott [6 ]
Coleman, Robert L. [3 ]
Moore, Kathleen N. [6 ]
Karlan, Beth Y. [2 ]
Sood, Anil K. [3 ]
Levine, Douglas A. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, 1275 York Ave, New York, NY 10065 USA
[2] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Samuel Oschin Comprehens Canc Inst, Womens Canc Program, Los Angeles, CA 90048 USA
[3] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol, Dept Canc Biol, Dallas, TX USA
[4] Univ Iowa, Holden Comprehens Canc Ctr, Dept Psychol & Brain Sci, Dept Obstet & Gynecol, Iowa City, IA 52242 USA
[5] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA
[6] Univ Oklahoma, Dept Obstet & Gynecol, Stephenson Oklahoma Canc Ctr, Div Gynecol Oncol, Oklahoma City, OK USA
关键词
Ovarian cancer; Long-term survival; Neoadjuvant chemotherapy; Surgical cytoreduction; Outcome; Survival; PROGNOSTIC-FACTORS; CANCER; MORTALITY; SURGERY; DISEASE;
D O I
10.1016/j.ygyno.2016.03.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. High-grade serous carcinoma (HGSC) generally presents at an advanced stage with poor long-term (LT) survival. Here we describe clinical features found in women surviving HGSC for ten or more years. Methods. A multi-center research consortium was established between five participating academic centers. Patient selection criteria included high-grade serous ovarian, fallopian tube, or peritoneal carcinoma with at least ten years of follow up. Non-serous, borderline tumors and low-grade serous subtypes were excluded. Results. The 203 identified LT ten-year survivors with HGSC were diagnosed at a median age of 57 years (range 37-84 years). The majority of patients had stage IIIC (72.4%) disease at presentation. Of those who underwent primary cytoreductive surgery, optimal cytoreduction was achieved in 143 (85.6%) patients. After a median follow up of 144 months, 88 (46.8%) patients did not develop recurrent disease after initial treatment. Unexpected findings from this survey of LT survivors includes 14% of patients having had suboptimal cytoreduction, 11% of patients having an initial platinum free interval of <12 months, and nearly 53% of patients having recurrent disease, yet still surviving more than ten years after diagnosis. Conclusions. LT survivors of HGSC of the ovary generally have favorable clinical features including optimal surgical cytoreduction and primary platinum sensitive disease. The majority of patients will develop recurrent disease, however many remained disease free for more than 10 years. Future work will compare the clinical features of this unusual cohort of LT survivors with the characteristics of HGSC patients having less favorable outcomes. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:260 / 263
页数:4
相关论文
共 50 条
  • [41] Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
    Arend, Rebecca C.
    Londono, Angelina I.
    Montgomery, Allison M.
    Smith, Haller J.
    Dobbin, Zachary C.
    Katre, Ashwini A.
    Martinez, Alba
    Yang, Eddy S.
    Alvarez, Ronald D.
    Huh, Warner K.
    Bevis, Kerri S.
    Straughn, J. Michael, Jr.
    Estes, Jacob M.
    Novak, Lea
    Crossman, David K.
    Cooper, Sara J.
    Landen, Charles N.
    Leath, Charles A., III
    MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 813 - 824
  • [42] High-grade serous carcinoma of the ovary
    Westfall, Danielle
    Roma, Andres A.
    Silva, Elvio G.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2009, 13 (04) : 285 - 290
  • [43] Axillary lymph-node metastases as the primary presentation of high-grade serous ovarian carcinoma: A case report
    Mirzaei, Monire
    Eshraghi, Abbas
    Ghoddoosi, Mahdiieh
    Fatemi, Maedeh Alsadat
    Eshraghi, Azhar
    Shenavaei, Sara
    Fazilat-panah, Danial
    CLINICAL CASE REPORTS, 2022, 10 (04):
  • [44] Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma
    Cohen, Samantha
    Mosig, Rebecca
    Moshier, Erin
    Pereira, Elena
    Rahaman, Jamal
    Prasad-Hayes, Monica
    Halpert, Richard
    Billaud, Jean-Noel
    Dottino, Peter
    Martignetti, John A.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (03) : 591 - 598
  • [45] Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma
    Matsumoto, Toshihide
    Oda, Yusuke
    Hasegawa, Yoshinori
    Hashimura, Miki
    Oguri, Yasuko
    Inoue, Hisako
    Yokoi, Ako
    Tochimoto, Masataka
    Nakagawa, Mayu
    Jiang, Zesong
    Saegusa, Makoto
    AMERICAN JOURNAL OF PATHOLOGY, 2021, 191 (10) : 1837 - 1850
  • [46] Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
    Vaksman, Olga
    Davidson, Ben
    Trope, Claes
    Reich, Reuven
    HUMAN PATHOLOGY, 2013, 44 (12) : 2677 - 2683
  • [47] Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
    Hollis, Robert L.
    Meynert, Alison M.
    Michie, Caroline O.
    Rye, Tzyvia
    Churchman, Michael
    Hallas-Potts, Amelia
    Croy, Ian
    McCluggage, W. Glenn
    Williams, Alistair R. W.
    Bartos, Clare
    Iida, Yasushi
    Okamoto, Aikou
    Dougherty, Brian
    Barrett, J. Carl
    March, Ruth
    Matakidou, Athena
    Roxburgh, Patricia
    Semple, Colin A.
    Harkin, D. Paul
    Kennedy, Richard
    Herrington, C. Simon
    Gourley, Charlie
    CLINICAL CANCER RESEARCH, 2022, 28 (16) : 3546 - 3556
  • [48] A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology
    Chen, Ming
    Jin, Ying
    Bi, Yalan
    Yin, Jie
    Wang, Yongxue
    Pan, Lingya
    ONCOTARGETS AND THERAPY, 2014, 7 : 1891 - 1899
  • [49] High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment
    Vivod, Gregor
    Merlo, Sebastjan
    Kovacevic, Nina
    CURRENT ONCOLOGY, 2024, 31 (04) : 1920 - 1935
  • [50] Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
    Norris, Eric J.
    Zhang, Qing
    Jones, Wendell D.
    DeStephanis, Darla
    Sutker, Ashley P.
    Livasy, Chad A.
    Ganapathi, Ram N.
    Tait, David L.
    Ganapathi, Mahrukh K.
    JOURNAL OF PATHOLOGY, 2019, 248 (03) : 352 - 362